November 2025

ENDOCRINOLOGY

INSIGHTS INTO MANAGING ADVERSE EFFECTS OF OBESITY MEDICATIONS

Incretin-based medications are transforming obesity treatment and improving outcomes in diabetes, cardiovascular, kidney and sleep apnea care. In a recent article published in JAMA, co-author Robert F. Kushner, MD, of Northwestern Medicine Endocrinology, and colleagues address the clinical management of adverse effects associated with this class of medications — specifically semaglutide and tirzepatide.
​
As these therapies become more integrated into obesity care, Dr. Kushner advocates for a balanced, evidence-based approach — leveraging their benefits while managing dosing and lifestyle adjustments to minimize side effects and support sustainable weight loss.
Read the full article
Robert Kushner, MD, Professor of Endocrinology and of Medical Education at Northwestern Medicine.

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like